Lupin Launches Dapagliflozin Tablets in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States following the approval for its Abbreviated New Drug Application from the U.S. FDA as bioequivalent to Farxiga® for the indications in the approved labeling.

Shares of Lupin Limited was last trading in BSE at Rs. 2332.70 as compared to the previous close of Rs. 2296.15. The total number of shares traded during the day was 38797 in over 7548 trades.

The stock hit an intraday high of Rs. 2336.95 and intraday low of 2290.50. The net turnover during the day was Rs. 90274867.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals DapagliflozinTablets USLaunch